FibroGen Inc
FGEN6.805USD
-0.085-1.23%
Market hours （ET）Quotes delayed by 15 min
27.50MMarket Cap
LossP/E TTM
More Details of FibroGen Inc Company
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Company Info
Ticker SymbolFGEN
Company nameFibroGen Inc
IPO dateNov 14, 2014
CEOMr. Thane Wettig
Number of employees225
Security typeOrdinary Share
Fiscal year-endNov 14
Address350 Bay Street
CitySAN FRANCISCO
Stock exchangeLondon Stock Exchange
CountryUnited States of America
Postal code94133
Phone14159781200
Websitehttps://www.fibrogen.com/
Ticker SymbolFGEN
IPO dateNov 14, 2014
CEOMr. Thane Wettig
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Thane Wettig
Mr. Thane Wettig
Chief Executive Officer, Director
Chief Executive Officer, Director
21.10K
+234.52%
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
16.10K
+393.71%
Mr. David Delucia
Mr. David Delucia
Chief Financial Officer
Chief Financial Officer
4.49K
-5.17%
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
1.36K
+32.20%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
1.26K
+35.78%
Ms. Christine L. Chung
Ms. Christine L. Chung
Senior Vice President, China Operations
Senior Vice President, China Operations
--
--
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thane Wettig
Mr. Thane Wettig
Chief Executive Officer, Director
Chief Executive Officer, Director
21.10K
+234.52%
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
16.10K
+393.71%
Mr. David Delucia
Mr. David Delucia
Chief Financial Officer
Chief Financial Officer
4.49K
-5.17%
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
1.36K
+32.20%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
1.26K
+35.78%
Ms. Christine L. Chung
Ms. Christine L. Chung
Senior Vice President, China Operations
Senior Vice President, China Operations
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
26.11M
88.16%
Europe
6.27M
21.17%
China
91.00K
0.31%
Japan - Related Party
-2.85M
-9.64%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jul 22
Updated: Tue, Jul 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.41%
The Vanguard Group, Inc.
4.41%
Acadian Asset Management LLC
3.87%
PRIMECAP Management Company
3.70%
BlackRock Institutional Trust Company, N.A.
2.30%
Other
77.31%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.41%
The Vanguard Group, Inc.
4.41%
Acadian Asset Management LLC
3.87%
PRIMECAP Management Company
3.70%
BlackRock Institutional Trust Company, N.A.
2.30%
Other
77.31%
Shareholder Types
Shareholders
Proportion
Investment Advisor
11.47%
Hedge Fund
10.71%
Investment Advisor/Hedge Fund
8.40%
Individual Investor
1.58%
Research Firm
0.34%
Venture Capital
0.09%
Pension Fund
0.01%
Family Office
0.01%
Other
67.39%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
277
1.32M
32.63%
-1.07M
2025Q1
349
1.54M
35.66%
-1.24M
2024Q4
354
38.15M
37.86%
-34.64M
2024Q3
363
47.69M
47.49%
-32.19M
2024Q2
377
57.63M
57.92%
-25.55M
2024Q1
379
62.46M
63.22%
-31.62M
2023Q4
378
71.59M
72.78%
-20.74M
2023Q3
393
71.13M
72.42%
-20.69M
2023Q2
420
83.19M
85.43%
-10.96M
2023Q1
450
83.25M
88.40%
-10.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
340.00K
8.41%
+68.00K
+25.00%
Mar 31, 2025
The Vanguard Group, Inc.
234.37K
5.8%
-714.00
-0.30%
Mar 31, 2025
Acadian Asset Management LLC
156.21K
3.87%
--
--
Mar 31, 2025
PRIMECAP Management Company
149.63K
3.7%
-35.01K
-18.96%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
93.06K
2.3%
-188.00
-0.20%
Mar 31, 2025
Marshall Wace LLP
88.50K
2.19%
+37.88K
+74.83%
Mar 31, 2025
Two Sigma Investments, LP
50.43K
1.25%
-10.93K
-17.82%
Mar 31, 2025
Geode Capital Management, L.L.C.
43.18K
1.07%
+846.00
+2.00%
Mar 31, 2025
Wettig (Thane)
21.10K
0.52%
+14.79K
+234.52%
Mar 31, 2025
Renaissance Technologies LLC
19.25K
0.48%
-35.10K
-64.58%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Global X Aging Population ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
View more
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Morningstar Small-Cap Value ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Global X Aging Population ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
